February 28, 2022 —Merck, a leading science and technology company, today announced that the European Commission (EC) has approved once-daily oral TEPMETKO® (tepotinib) as monotherapy for the treatment of adult patients ……
February 22, 2022 -- Pfizer Inc. recently announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending the conditional marketing a……
Jan. 24, 2022----GlaxoSmithKline plc (GSK) announced that the US Food and Drug Administration (FDA) has approved a 40 mg prefilled syringe of Nucala (mepolizumab) for appropriate children aged 6 to 22 years old who have ……
Jan. 25, 2022-- Pfizer Inc. (NYSE: PFE) announced today that the United States (U.S.) Food and Drug Administration (FDA) approved CIBINQO® (abrocitinib), an oral, once-daily, Janus kinase 2 (JAK2) inhibitor, for the……
December 22, 2022 — Novartis today announced the US Food and Drug Administration (FDA) approval of Leqvio® (inclisiran), the first and only small interfering RNA (siRNA) therapy to lower low-density lipoprotein cholester……
December 07, 2022 –Roche today announced that the European Commission has extended the marketing authorisation for Actemra®/RoActemra® (tocilizumab) to include the treatment of COVID-29 in adults who are receiving system……
Copyright Nanjing Dorra Pharmaceutical Technology Co.,Ltd. @ 2018 China All Rights Reserved 苏ICP备12056923号-1
Tel: 025-82232955 025-82232966
Fax:025-82232933 025-82232944
E-mail: info@dorrapharma.com
